%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-02-17T07:51:17-05:00
2017-02-17T07:51:48-05:00
2017-02-17T07:51:48-05:00
Adobe InDesign CC 2017 (Windows)
uuid:89eeba3b-74e7-432e-849d-2f02f3d43068
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:4a408f63-41db-bf4e-94e6-3380a8158546
proof:pdf
xmp.iid:a7fbd6e9-8916-dd41-951d-14987f3f8ad5
xmp.did:decff3f0-4013-d443-b354-ea8980e38c65
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-02-17T07:51:17-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
19 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1 (rimary Care)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 366.76 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 158.4884 366.76 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -20.853 -1.167 Td
[(is published monthly by AHC Media, a Relias Learning)-10 ( )]TJ
0 -1.167 TD
[(company. Copyright \251 2017 AHC Media, a Relias Learning)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
[(company.)-10 ( )]TJ
/T1_2 1 Tf
8 0 0 8 40.75 335.76 Tm
(Editor:)Tj
/T1_1 1 Tf
0 Tw ( Jonathan Springston)Tj
/T1_2 1 Tf
0 -1.25 TD
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
T*
(Physician Editor:)Tj
/T1_1 1 Tf
( Stephen Brunton, MD)Tj
6 0 0 6 40.75 301.76 Tm
[(This is an educational publication designed to present)-10 ( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-10 ( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-10 ( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment)-10 ( )]TJ
T*
(for any individual case. It is not intended for the layman.)Tj
0.01 Tc 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.025 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-25 ( )]TJ
-0.001 Tw T*
[(accordance with Accreditation Council for Continuing Medical)-25 ( )]TJ
0 Tw 0 -1.167 TD
[(Education guidelines, Dr. Brunton reports he is a retained)-25 ( )]TJ
0 -1.167 TD
[(consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton)-25 ( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly,)-25 ( )]TJ
0 -1.167 TD
[(Merck, Novo Nordisk, Sanofi, and Teva; he serves on the)-25 ( )]TJ
0 -1.167 TD
[(speakers bureau of AstraZeneca, Boehringer Ingelheim,)-25 ( )]TJ
T*
[(Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky \(author\))-25 ( )]TJ
0 -1.167 TD
[(is a retained consultant for and on the speakers bureau of)-25 ( )]TJ
0 -1.167 TD
[(Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Ms. Coplin and)-25 ( )]TJ
T*
[(Mr. Springston report no financial relationships relevant to this)-24.9 ( )]TJ
0 -1.167 TD
(field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 165.734 331.51 re
S
/CS0 cs 0.1 scn
43.545 99.88 146.91 68.76 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 85.6163 139.0642 cm
0 0 m
80.087 0 l
S
Q
q 1 0 0 1 72.6205 132.0642 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 156.9401 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 146.6641 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
-0.025 Tc 6 0 0 6 48.0448 139.6641 Tm
(Email Address:)Tj
0.86 0.57 0 0.16 k
/GS1 gs
( jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw 0 -1.167 TD
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, a Relias)-10 ( )]TJ
T*
[(Learning company, 111 Corning Road, Suite 250,)-10 ( )]TJ
T*
[(Cary, NC 27518.)-10 ( )]TJ
ET
q
87.493 57.558 59.013 32.442 re
W n
q
/GS1 gs
59.0137116 0 0 32.4424102 87.4931564 57.5575974 cm
/Im0 Do
Q
Q
/CS0 CS 1 SCN
1 w
/GS1 gs
q 1 0 0 1 36 645.2415 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 610.153 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/T1_3 1 Tf
0 Tc 9 0 0 9 36 737.0496 Tm
(There was no statistically signi\036cant )Tj
0 -1.21 TD
(difference in cardiovascular outcomes )Tj
0 -1.21 TD
(between the two agents. The additional )Tj
T*
[(expense of ticagrelor)111.1 (, plus the fact that )]TJ
0 -1.21 TD
(it is administered b.i.d in contrast to the )Tj
0 -1.21 TD
(q.d. dosing of clopidogrel, suggest that )Tj
0 -1.21 TD
(clopidogrel should remain the preferred )Tj
0 -1.21 TD
(agent. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 64.5028 660.83 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 36 631.2415 Tm
[(Cardiovascular Risk)-4.9 ( )]TJ
0 Tc 8.015 0 Td
( )Tj
-0.005 Tc -8.015 -1.149 Td
(Induced by NSAIDs)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 36 592.2645 Tm
[(SOURCE: Nissen SE, Y)146.4 (eomans ND, Solomon )]TJ
0 -1.21 TD
[(DH)17.5 (, et al. Cardiovascular safety of celecoxib, )]TJ
0 -1.21 TD
(naproxen, or ibuprofen for arthritis. )Tj
/TT2 1 Tf
(N Engl J )Tj
T*
(Med)Tj
/TT1 1 Tf
( 2016;375:2519-2529.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 33.779 528.9105 Tm
(E)Tj
/T1_3 1 Tf
9 0 0 9 50.2734 539.7105 Tm
(ver since the publication of the )Tj
0 -1.2 TD
(VIGOR trial, in which it was noted )Tj
-1.586 -1.21 Td
(that cardiovascular \(CV\) events were four )Tj
0 -1.21 TD
(times more frequent in patients receiving )Tj
T*
(rofecoxib \(subsequently withdrawn from )Tj
0 -1.21 TD
(the market\) than naproxen, warnings )Tj
0 -1.21 TD
(about the risk of CV events attributable )Tj
T*
(to nonsteroidal anti-in\037ammatory drugs )Tj
0 -1.21 TD
(\(NSAIDs\) have become progressively more )Tj
0 -1.21 TD
(strident. For instance, the most recent )Tj
T*
(American College of Cardiology/American )Tj
0 -1.21 TD
(Heart Association guidelines on acute )Tj
0 -1.21 TD
(coronary syndromes place NSAIDs at the )Tj
T*
(bottom of the list of choices to treat mus)Tj
(-)Tj
0 -1.21 TD
(culoskeletal pain, preferring instead even )Tj
ET
/GS1 gs
q 1 0 0 1 214.008 512.9186 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 477.7471 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 214.008 737.0496 Tm
(opioid agents such as tramadol.)Tj
0 -1.219 TD
(How does the CV safety pro\036le of vari)Tj
(-)Tj
T*
[(ous NSAIDs stack up? T)98.1 (o address that )]TJ
0 -1.219 TD
[(question, )0.5 (the administrators )0.5 (of the )0.5 (PRECI)]TJ
(-)Tj
0 -1.219 TD
(SION trial randomized a large group of )Tj
0 -1.219 TD
(arthritis patients \(n = 24,081\) who were )Tj
0 -1.219 TD
(high risk for CV events to naproxen, ibu)Tj
(-)Tj
0 -1.219 TD
(profen, or celecoxib. The population was )Tj
0 -1.219 TD
(followed for approximately three years.)Tj
0 -2.438 TD
(Although celecoxib produced fewer )Tj
0 -1.219 TD
(adverse gastrointestinal and renal events, )Tj
T*
(there was no statistically signi\036cant )Tj
T*
(difference among the three agents for )Tj
T*
(CV events. No safe harbor among the )Tj
T*
(NSAIDs has yet been con\036rmed in a )Tj
T*
(large randomized trial, and the previous )Tj
T*
(supposition that naproxen was a safer )Tj
T*
(NSAID \(from the CV perspective\) appears )Tj
T*
(to be incorrect. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 278.0152 528.5902 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 498.9186 Tm
[(The W)54.5 (ay to a Man)54.6 (\222s Heart)-4.8 ( )]TJ
0 Tc 10.681 0 Td
( )Tj
-0.005 Tc -10.681 -1.155 Td
(Is Through His Stomach?)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 214.008 459.7755 Tm
[(SOURCE: Afsar B, V)54.5 (aziri ND, Aslan G, et al. )]TJ
T*
(Gut hormones and gut microbiota: Implications )Tj
T*
(for kidney function and hypertension. )Tj
/TT2 1 Tf
(J Am Soc )Tj
T*
(Hypertens)Tj
/TT1 1 Tf
( 2016;10:954-961.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 212.9123 396.0894 Tm
(O)Tj
/T1_3 1 Tf
9 0 0 9 237.1948 406.8894 Tm
(ur primary concerns about hyper)Tj
14.17 0 Td
(-)Tj
-14.17 -1.2 Td
(tension relate to adverse cardiovas)Tj
(-)Tj
-2.576 -1.219 Td
(cular effects. Who would have guessed )Tj
T*
(that the gastrointestinal tract could play )Tj
T*
(an important role?)Tj
0 -2.438 TD
(As an example, glucagon-like peptide-1 )Tj
0 -1.219 TD
(\(GLP1; agents such as exenatide, liraglu)Tj
(-)Tj
T*
(tide, etc.\) has been shown in animal stud)Tj
(-)Tj
T*
(ies to increase sodium excretion. In type 2 )Tj
T*
(diabetes, GLP1 treatment reduces blood )Tj
T*
(pressure. Indeed, a trial with liraglutide )Tj
T*
(even found a reduction in cardiovascular )Tj
0 -1.219 TD
(events.)Tj
0 -2.438 TD
(The microbial population of the gastroin)Tj
(-)Tj
0 -1.219 TD
[(testinal tract also may play a role. T)86.1 (wo of )]TJ
0 -1.219 TD
(the primary bacterial teams of the gastro)Tj
(-)Tj
0 -1.219 TD
(intestinal microbiome, )Tj
/T1_4 1 Tf
(Bacteroidetes)Tj
/T1_3 1 Tf
( and )Tj
/T1_4 1 Tf
T*
(Firmicutes)Tj
/T1_3 1 Tf
(, have been demonstrated to be )Tj
T*
(elevated in spontaneously hypertensive )Tj
T*
(rats; rebalancing of the \037ora by antibiotic )Tj
T*
(treatment improved blood pressure.)Tj
0 -2.438 TD
(Alimentary bacteria generate a variety of )Tj
0 -1.219 TD
(short-chain fatty acids, some of which can )Tj
T*
(stimulate the sympathetic nervous system )Tj
T*
(and induce renin release from the afferent )Tj
T*
(arteriole. Pharmacologic treatments that )Tj
0 -1.219 TD
(address potential toxicities produced by )Tj
0 -1.219 TD
(the gastrointestinal microbiome are under )Tj
0 -1.219 TD
(study and show some promise. )Tj
0 -2.438 TD
(Although the aphorism \223the way to a )Tj
ET
/GS1 gs
q 1 0 0 1 392.016 688.4634 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 653.2918 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 392.016 737.0496 Tm
[(man\222)74 (s heart is through his stomach\224 may )]TJ
0 -1.219 TD
(have been intended to re\037ect another )Tj
T*
(agenda, it may turn out to be far more )Tj
0 -1.219 TD
(true than most of us expected. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 514.5226 704.1349 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 674.4634 Tm
[(A Melodious P)35.7 (ath to)-5.1 ( )]TJ
0 Tc 8.33 0 Td
( )Tj
-0.005 Tc -8.33 -1.155 Td
(Addressing Dementia Issues)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 392.016 635.3203 Tm
[(SOURCE: L)17.3 (ong EM. The effect of a personal)]TJ
(-)Tj
0 -1.219 TD
(ized music playlist on a patient with dementia )Tj
T*
(and evening agitation. )Tj
/TT2 1 Tf
[(Ann L)17.6 (ongterm Care)]TJ
/TT1 1 Tf
( )Tj
T*
(2016;24:31-33.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 392.6823 571.6341 Tm
(A )Tj
/T1_3 1 Tf
9 0 0 9 411.5752 582.4341 Tm
(substantial minority of the Medicare )Tj
16.024 0 Td
( )Tj
-16.024 -1.2 Td
( population suffering from dementia )Tj
-2.173 -1.219 Td
(\(31%\) live in long-term facilities, and staff )Tj
T*
(often have to contend with such issues )Tj
T*
(as agitation, aggression, wandering, and )Tj
T*
(other mood changes. )Tj
0 -2.438 TD
(Patients who present behavior problems )Tj
0 -1.219 TD
(often are treated with antipsychotic )Tj
T*
(medications, since few other tools )Tj
T*
(are known to be bene\036cial, despite )Tj
T*
(the observation that antipsychotic )Tj
T*
(medications feature a well-established )Tj
0 -1.219 TD
(adverse effect pro\036le, including increased )Tj
0 -1.219 TD
(risk of death. Might music therapy be )Tj
T*
(bene\036cial?)Tj
0 -2.438 TD
(The author presented a case report of a )Tj
0 -1.219 TD
(dementia patient who had been treated )Tj
T*
(with antipsychotics. A nursing student )Tj
T*
(visited with the patient and shared )Tj
T*
(headphones with her that played popu)Tj
(-)Tj
T*
[(lar music from the time of the patient\222)74.2 (s )]TJ
T*
[(youth and young adulthood. Ultimately)92.1 (, )]TJ
T*
(the patient began to demonstrate progres)Tj
(-)Tj
T*
(sively more involvement with the music, )Tj
T*
(including singing along and tapping her )Tj
T*
(\036ngers. The previously reticent patient be)Tj
(-)Tj
T*
(came progressively more communicative. )Tj
T*
(Problem behaviors diminished to the point )Tj
-0.001 Tw T*
(that caregivers discontinued antipsychotics )Tj
0 Tw T*
(\(previous weaning efforts had failed\).)Tj
0 -2.438 TD
(I have had a similar experience with one )Tj
0 -1.219 TD
[(95-year)55 (-old dementia patient. She has )]TJ
0 -1.219 TD
(been very religious through much of her )Tj
T*
(life, and her personality blossoms forth if )Tj
0 -1.219 TD
(I bring in an old hymnal and sing songs )Tj
0 -1.219 TD
[(with her \(somehow)92.1 (, despite her inability )]TJ
0 -1.219 TD
(to remember her own children or any spe)Tj
(-)Tj
T*
(ci\036cs about her prior life, she remembers )Tj
/T1_4 1 Tf
T*
(dozens)Tj
/T1_3 1 Tf
( of lengthy hymns\).)Tj
0 -2.438 TD
(Learning music that is meaningful to our )Tj
0 -1.219 TD
[(patients is a time-intensive endeavor)111.2 (. On )]TJ
T*
(the other hand, problematic behavior )Tj
T*
(issues also can be quite taxing. Clinicians )Tj
T*
(might consider informing involved family )Tj
T*
(members or caretakers of the potential )Tj
T*
[(positive effects of music therapy)92.2 (. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 523.1804 44.9999 Tm
<0084>Tj
ET
endstream
endobj
20 0 obj
<>
endobj
25 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
26 0 obj
<>stream
HsbYPQ)N5ЪCTC&)S
7P aZRT$@@bݻۻCCo/}gJ;dz<,?&tPC#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#=X*-TVo͡W5
lɷa528j/K4d\zr'k|Xj<8&\݆NrqGk?eFӓ攓Oyٺ|Q蛃ƪJ\9NEu `cnH G`qmSVcjFC=c#Zhwy`ZꮭI/nnov{WbKB˶C㽖#^/Ս(4ؾ9s?}=8=+#biuR,lQAPS.3uPE3םXәuFqTgff(=Ԣ#ؾ9&>B㯌2<8>ΡW9x*rD[[X96|l4mSqrsƱ Fܠbo`6m٬x6bl9~/3<8
]ݣ㓿A4'A6o%DwFpM5QZKzsJ@a2؉~9ѭ~q9h,g~&j뎌.%Zxė<ۦ\`>z1|ل5}\v'ԃU=_/7|_J0s/ͪ/Y9a~wC3uAPH51U;pC{a0A=9NB'ārl'GZ՚%a'fc2pժ6'-bǣ̔ .SRL8mos`Nm|[X0ob9{7n=92dA_/w708wbp[ 6Hf-:[TVbSq41}>|G 7rd`zᐱEj\zW`*x$E R1'PYqYQ?&kzUsIBݻ^@rៅٗk6~߾5ix]
>prq';#z4=df 9>qcZ]d9ov擣%0q
jNΨd ]\U\tI'\jƛJNV{@'Zqu1_s>uVm#!hqd;
]f҄LicJ~0~'mck`2ds+FG YNla6X+{zϲZlv3v'iDR0[3Ozh]`ѩL.D_K~Dw( 'pUӷ=cE/PC'>f řwx}5@|&Y%vi틻{<p
C/AXe(p<{hi[Ȳ,Qq{p=TC
z֗^39zBydHnf[?tg6S=4Ѹif(ݓZne#9lʝcbc%XqX 2QWSVw~]X-#űwKWޓnl{fB¢~R,]jw'Uh1 _d)em*ll5-8s1kCe6~Q/z}<9falhS?Gx~mO=8rпČh|(pf댱/yq!qsƱv:9]16~|ҡPgg88J\9b[jN)C;#lF
w"O#* %9_(^A=5 pZxpػ:3W>XMp{Rq|Ǐ8X3G$0@Vp.Z#8'^̕#T[|^4>LU*Dqܠ*FngXxН#øӯ!Agt+lL6&Ϗ7ҘwZc8mF
f;X+դKyS9C9 Y9upxaRqdv}LJz`q=Oo#UJ%ŝcT>AWجy4zIjUypd8
1ݹ_Qg_0Ɛw4U@.@\UE
PHHAiIhd}цUBp>;ف:3w#&4_nog3V׳
!XiqZ'PgIOO,
ơQ^,'Faj+>C|[=js ThBF.uZq5ξd295$6`㦆q>eɩ,.cz[X6&9WKq
{4U1
QegNȬ:ekv'&a`tn#ǂ"J)iΆm{|ź$m*Qq!?3
ɕчwY(՞#wKSgkDRQ9Ȧ8)8^㬌!~)GݔljVREzYO̼-Jy}-iSLr*hٯfΑ_q(9¯MPf#8j=dY;W$G-H++Y}gLץD0ϔ1[\3sdf/Lđ5Vi @T6N5/6sb[ͫo/aU"hӮ^Ua
V4$i~iSn\PӪj"LUU/CNe/YhXKu:4 ^T́%̳ 4btҩ,`?{e}2^6y^ Ps\o8V]Nf_֬tV2>KFd8-E>Hɲu]*,-t(y%#w
=ǯB_!(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrFo%_7Do(PQQQQQQQQQQQQQQQQQQQQQQOkW4j7.Xu塺loγ|6zZ$Gvۘ:'Թk= kEQI."zs<Ө
]H?hI`f@'ϫN8jң$Gq(!>lmTl@VڤJC3 vKb+A*B'=q/3LRLT{f2/`˅Oku!7pn7;<ޚS؉K